Alnylam Pharmace. buy stefan
Start price
01.10.19
/
50%
€68.16
Target price
04.11.21
-
Performance (%)
134.45%
End price
05.11.21
€159.80
Summary
This prediction ended on 05.11.21 with a price of €159.80. With a performance of 134.45% the BUY prediction by stefan was a big success. stefan has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | 11.008% | 11.008% | 19.967% | 39.932% |
| iShares Core DAX® | 0,39 % | 0,15 % | 10,96 % | 58,44 % |
| iShares Nasdaq 100 | 1,31 % | -2,55 % | -0,61 % | 84,24 % |
| iShares Nikkei 225® | -0,46 % | 6,89 % | 26,75 % | 63,40 % |
| iShares S&P 500 | 1,31 % | -1,16 % | -0,04 % | 58,22 % |
Comments by stefan for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.
Die von stefan gewählte maximale Laufzeit wurde überschritten